GSK
GSK plc
Stock
$47.03−0.15 (−0.32%)Close Oct 2, 2026
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | £32.7B | £31.4B | £30.3B | £29.3B | £24.7B | £24.4B | £33.8B | £30.8B | £30.2B | £27.9B | £23.9B |
| Cost of revenue | £9.0B | £9.0B | £8.6B | £9.6B | £8.2B | £7.9B | £11.9B | £10.2B | £10.3B | £9.3B | £8.9B |
| Gross profit | £23.7B | £22.3B | £21.8B | £19.8B | £16.5B | £16.4B | £21.9B | £20.6B | £19.8B | £18.6B | £15.1B |
| R&D | £7.5B | £6.4B | £6.2B | £5.5B | £5.0B | £4.8B | £4.6B | £3.9B | £4.5B | £3.6B | £3.6B |
| SG&A | £9.1B | £11.0B | £9.4B | £8.4B | £7.1B | £7.4B | £11.4B | £9.9B | £9.7B | £9.4B | £9.2B |
| Other operating expenses | — | £891M | — | — | £87M | — | — | £1.3B | £1.6B | £3.0B | — |
| Operating income | £7.9B | £4.0B | £6.7B | £6.4B | £4.4B | £6.0B | £7.0B | £5.5B | £4.1B | £2.6B | £10.3B |
| Non-operating income | −£531M | −£544M | −£681M | −£805M | −£758M | −£809M | −£740M | −£683M | −£562M | −£659M | £204M |
| Pretax income | £7.4B | £3.5B | £6.1B | £5.6B | £3.6B | £5.2B | £6.2B | £4.8B | £3.5B | £1.9B | £10.5B |
| Taxes | £1.7B | £902M | £1.1B | −£9.3B | −£786M | −£579M | £1.6B | £1.2B | £2.0B | £1.0B | £2.1B |
| Net income | £5.7B | £2.6B | £4.9B | £15.0B | £4.4B | £5.7B | £4.6B | £3.6B | £1.5B | £912M | £8.4B |
| Diluted EPS | £1.39 | £0.62 | £1.20 | £3.66 | £1.08 | £1.43 | £0.93 | £0.73 | £0.31 | £0.19 | £1.72 |
| Diluted shares | 4.12B | 4.14B | 4.11B | 4.08B | 4.05B | 4.03B | 5.02B | 4.97B | 4.94B | 4.91B | 4.89B |
| Revenue growth | +4.1% | +3.5% | +3.4% | +18.7% | +1.4% | −27.8% | +9.5% | +2.1% | +8.2% | +16.6% | — |
| Gross margin | 72.4% | 71.2% | 71.8% | 67.4% | 66.9% | 67.4% | 64.9% | 66.8% | 65.7% | 66.7% | 63.0% |
| Operating margin | 24.3% | 12.8% | 22.2% | 21.9% | 17.6% | 24.6% | 20.6% | 17.8% | 13.5% | 9.3% | 43.1% |
| Net margin | 17.5% | 8.2% | 16.2% | 51.0% | 17.8% | 23.6% | 13.8% | 11.8% | 5.1% | 3.3% | 35.2% |